[1]
|
Nishida, T., Yoshinaga, S., Takahashi, T. and Naito, Y. (2021) Recent Progress and Challenges in the Diagnosis and Treatment of Gastrointestinal Stromal Tumors. Cancers, 13, Article 3158. https://doi.org/10.3390/cancers13133158
|
[2]
|
Mantese, G. (2019) Gastrointestinal Stromal Tumor: Epidemiology, Diagnosis, and Treatment. Current Opinion in Gastroenterology, 35, 555-559. https://doi.org/10.1097/MOG.0000000000000584
|
[3]
|
Hirota, S., Isozaki, K., Moriyama, Y., et al. (1998) Gain-of-Function Mutations of c-Kit in Human Gastrointestinal Stromal Tumors. Science, 279, 577-580. https://doi.org/10.1126/science.279.5350.577
|
[4]
|
Heinrich, M.C., Corless, C.L., Duensing, A., et al. (2003) PDGFRA activating Mutations in Gastrointestinal Stromal Tumors. Science, 299, 708-710. https://doi.org/10.1126/science.1079666
|
[5]
|
Agaram, N.P., Wong, G.C., Guo, T., et al. (2008) Novel V600E BRAF Mutations in Imatinib-Naive and Imatinib-Resistant Gastrointestinal Stromal Tumors. Genes, Chromosomes & Cancer, 47, 853-859.
https://doi.org/10.1002/gcc.20589
|
[6]
|
Agaimy, A., Terracciano, L.M., Dirnhofer, S., et al. (2009) V600E BRAF Mutations Are Alternative Early Molecular Events in a Subset of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumours. Journal of Clinical Pathology, 62, 613-616. https://doi.org/10.1136/jcp.2009.064550
|
[7]
|
Lasota, J., Fe-lisiak-Golabek, A., Wasag, B., et al. (2016) Frequency and Clinicopathologic Profile of PIK3CA Mutant GISTs: Molec-ular Genetic Study of 529 Cases. Modern Pathology, 29, 275-282.
https://doi.org/10.1038/modpathol.2015.160
|
[8]
|
Shi, S.S., Wu, N., He, Y., et al. (2017) EGFR Gene Mutation in Gastrointestinal Stromal Tumours. Histopathology, 71, 553-561. https://doi.org/10.1111/his.13251
|
[9]
|
Brenca, M., Rossi, S., Polano, M., et al. (2016) Transcriptome Sequencing Identifies ETV6-NTRK3 as a Gene Fusion Involved in GIST. The Journal of Pathology, 238, 543-549. https://doi.org/10.1002/path.4677
|
[10]
|
Shi, E., Chmielecki, J., Tang, C.M., et al. (2016) FGFR1 and NTRK3 Actionable Alterations in “Wild-Type” Gastrointestinal Stromal Tumors. Journal of Translational Medicine, 14, Article No. 339.
https://doi.org/10.1186/s12967-016-1075-6
|
[11]
|
Boikos, S.A., Pappo, A.S., Killian, J.K., et al. (2016) Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncology, 2, 922-928. https://doi.org/10.1001/jamaoncol.2016.0256
|
[12]
|
Ma, G.L., Murphy, J.D., Martinez, M.E., et al. (2015) Epidemi-ology of Gastrointestinal Stromal Tumors in the Era of Histology Codes: Results of a Population-Based Study. Cancer Epidemiology, Biomarkers & Prevention, 24, 298-302.
https://doi.org/10.1158/1055-9965.EPI-14-1002
|
[13]
|
Von Mehren, M. and Joensuu, H. (2018) Gastrointestinal Stromal Tumors. Journal of Clinical Oncology, 36, 136-143.
https://doi.org/10.1200/JCO.2017.74.9705
|
[14]
|
Janeway, K.A., Kim, S.Y., Lodish, M., et al. (2011) Defects in Succinate Dehydrogenase in Gastrointestinal Stromal Tumors Lacking KIT and PDGFRA Mutations. Proceedings of the National Academy of Sciences of the United States of America, 108, 314-318. https://doi.org/10.1073/pnas.1009199108
|
[15]
|
Ranchod, M. and Kempson, R.L. (1977) Smooth Muscle Tumors of the Gastrointestinal Tract and Retroperitoneum: A Pathologic Analysis of 100 Cases. Cancer, 39, 255-262.
https://doi.org/10.1002/1097-0142(197701)39:1<255::AID-CNCR2820390139>3.0.CO;2-H
|
[16]
|
Miettinen, M. (1988) Gastrointestinal Stromal Tumors. An Immunohistochemical Study of Cellular Differentiation. American Journal of Clinical Pathology, 89, 601-610. https://doi.org/10.1093/ajcp/89.5.601
|
[17]
|
Mazur, M.T. and Clark, H.B. (1983) Gastric Stromal Tumors Reappraisal of Histogenesis. The American Journal of Surgical Pathology, 7, 507-520. https://doi.org/10.1097/00000478-198309000-00001
|
[18]
|
Dematteo, R.P., Lewis, J.J., Leung, D., et al. (2000) Two Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival. Annals of Sur-gery, 231, 51.
https://doi.org/10.1097/00000658-200001000-00008
|
[19]
|
Wu, J., Zhou, H., Yi, X., et al. (2021) Targeted Deep Sequencing Reveals Unrecognized KIT Mutation Coexistent with NF1 Deficiency in GISTs. Cancer Management and Research, 13, 297-306. https://doi.org/10.2147/CMAR.S280174
|
[20]
|
Brcic, I., Kashofer, K., Skone, D. and Liegl-Atzwanger, B. (2019) KIT Mutation in a Naïve Succinate Dehydrogenase-Deficient Gastric GIST. Genes, Chro-mosomes & Cancer, 58, 798-803. https://doi.org/10.1002/gcc.22768
|
[21]
|
Nishida, T., Doi, T. and Naito, Y. (2014) Tyrosine Kinase Inhibitors in the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors. Expert Opin-ion on Pharmacotherapy, 15, 1979-1989.
https://doi.org/10.1517/14656566.2014.937707
|
[22]
|
Rubin, B.P., Heinrich, M.C. and Corless, C.L. (2007) Gas-trointestinal Stromal Tumour. The Lancet, 369, 1731-1741.
https://doi.org/10.1016/S0140-6736(07)60780-6
|
[23]
|
Heinrich, M.C., Griffith, D.J., Druker, B.J., et al. (2000) In-hibition of c-Kit Receptor Tyrosine Kinase Activity by STI 571, a Selective Tyrosine Kinase Inhibitor. Blood, 96, 925-932. https://doi.org/10.1182/blood.V96.3.925
|
[24]
|
Demetri, G.D., Von Mehren, M., Blanke, C.D., et al. (2002) Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. The New England Journal of Medicine, 347, 472-480.
https://doi.org/10.1056/NEJMoa020461
|
[25]
|
Kelly, C.M., Gutierrez Sainz, L. and Chi, P. (2021) The Management of Metastatic GIST: Current Standard and Investigational Therapeutics. Journal of Hematology & Oncology, 14, Article No. 2.
https://doi.org/10.1186/s13045-020-01026-6
|
[26]
|
Verweij, J., Casali, P.G., Zalcberg, J., et al. (2004) Progres-sion-Free Survival in Gastrointestinal Stromal Tumours with High-Dose Imatinib: Randomised Trial. The Lancet, 364, 1127-1134. https://doi.org/10.1016/S0140-6736(04)17098-0
|
[27]
|
Blanke, C.D., Rankin, C., Demetri, G.D., et al. (2008) Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate at Two Dose Levels in Patients with Unre-sectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033. Journal of Clinical Oncology, 26, 626-632.
https://doi.org/10.1200/JCO.2007.13.4452
|
[28]
|
Von Mehren, M., Randall, R.L., Benjamin, R.S., et al. (2014) Gastrointestinal Stromal Tumors, Version 2.2014. Journal of the National Comprehensive Cancer Network, 12, 853-862. https://doi.org/10.6004/jnccn.2014.0080
|
[29]
|
Casali, P.G., Abecassis, N., Aro, H.T., et al. (2018) Gastrointestinal Stromal Tumours: ESMO-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 29, iv267.
|
[30]
|
Smith, B.D., Kaufman, M.D., Lu, W.P., et al. (2019) Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell, 35, 7387-51.E9.
https://doi.org/10.1016/j.ccell.2019.04.006
|
[31]
|
Evans, E.K., Gardino, A.K., Kim, J.L., et al. (2017) A Precision Therapy against Cancers Driven by KIT/PDGFRA Mutations. Science Translational Medicine, 9, eaao1690. https://doi.org/10.1126/scitranslmed.aao1690
|
[32]
|
Tan, Y., Tan, L., Lu, J., et al. (2017) Endoscopic Resection of Gastric Gastrointestinal Stromal Tumors. Translational Gastroenterology and Hepatology, 2, Article 115. https://doi.org/10.21037/tgh.2017.12.03
|
[33]
|
Madhusudhan, K.S. and Das, P. (2022) Mesenchymal Tumors of the Stomach: Radiologic and Pathologic Correlation. Abdominal Radiology, 47, 1988-2003. https://doi.org/10.1007/s00261-022-03498-1
|
[34]
|
Blay, J.Y., Kang, Y.K., Nishida, T. and von Mehren, M. (2021) Gastrointestinal Stromal Tumours. Nature Reviews Disease Primers, 7, Article No. 22. https://doi.org/10.1038/s41572-021-00254-5
|
[35]
|
Nishida, T., Blay, J.Y., Hirota, S., et al. (2016) The Standard Diagnosis, Treatment, and Follow-Up of Gastrointestinal Stromal Tumors Based on Guidelines. Gastric Cancer, 19, 3-14. https://doi.org/10.1007/s10120-015-0526-8
|
[36]
|
Zalupski, M., Metch, B., Balcerzak, S., et al. (1991) Phase III Comparison of Doxorubicin and Dacarbazine Given by Bolus versus Infusion in Patients with Soft-Tissue Sarcomas: A Southwest Oncology Group Study. Journal of the National Cancer Institute, 83, 926-932. https://doi.org/10.1093/jnci/83.13.926
|
[37]
|
Ryan, D.P., Puchalski, T., Supko, J.G., et al. (2002) A Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients with Gastrointestinal Stromal Tumors. The Oncologist, 7, 531-538. https://doi.org/10.1634/theoncologist.7-6-531
|
[38]
|
Trent, J.C., Beach, J., Burgess, M.A., et al. (2003) A Two-Arm Phase II Study of Temozolomide in Patients with Advanced Gastrointestinal Stromal Tumors and Other Soft Tissue Sarcomas. Cancer, 98, 2693-2699.
https://doi.org/10.1002/cncr.11875
|
[39]
|
Lamba, G., Ambrale, S., Lee, B., et al. (2012) Recent Advances and Novel Agents for Gastrointestinal Stromal Tumor (GIST). Journal of Hematology & Oncology, 5, Article No. 21. https://doi.org/10.1186/1756-8722-5-21
|
[40]
|
年中国胃肠道间质瘤病理共识意见专家组. 中国胃肠道间质瘤诊断治疗专家共识(2017年版)病理解读[J]. 中华病理学杂志, 2018, 47(1): 2-6.
|
[41]
|
Miettinen, M., Wang, Z.F. and Lasota, J. (2009) DOG1 Antibody in the Differential Diagnosis of Gastrointestinal Stromal Tumors: A Study of 1840 Cases. The American Journal of Surgical Pathology, 33, 1401-1408.
https://doi.org/10.1097/PAS.0b013e3181a90e1a
|
[42]
|
Davey, M.G., Hynes, S.O., Kerin, M.J., et al. (2021) Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. Cancers, 13, Article 4455. https://doi.org/10.3390/cancers13174455
|
[43]
|
Luchini, C., Pantanowitz, L., Adsay, V., et al. (2022) Ki-67 As-sessment of Pancreatic Neuroendocrine Neoplasms: Systematic Review and Meta-Analysis of Manual vs. Digital Pa-thology Scoring. Modern Pathology, 35, 712-720.
https://doi.org/10.1038/s41379-022-01055-1
|
[44]
|
Wang, J.P., Liu, L., Li, Z.A., et al. (2021) Ki-67 Labelling Index Is Related to the Risk Classification and Prognosis of Gastrointestinal Stromal Tumours: A Retrospective Study. Gas-troenterologia y Hepatologia, 44, 103-114.
https://doi.org/10.1016/j.gastrohep.2020.05.022
|
[45]
|
Fletcher, C.D., Berman, J.J., Corless, C., et al. (2002) Diag-nosis of Gastrointestinal Stromal Tumors: A Consensus Approach. International Journal of Surgical Pathology, 10, 81-89. https://doi.org/10.1177/106689690201000201
|
[46]
|
Miettinen, M. and Lasota, J. (2005) KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation. Ap-plied Immunohistochemistry & Molecular Morphology, 13, 205-220.
https://doi.org/10.1097/01.pai.0000173054.83414.22
|
[47]
|
Hirota, S. (2018) Differential Diagnosis of Gastrointes-tinal Stromal Tumor by Histopathology and Immunohistochemistry. Translational Gastroenterology and Hepatology, 3, Article 27. https://doi.org/10.21037/tgh.2018.04.01
|
[48]
|
Casali, P.G. and Blay, J.Y. (2010) Gastrointestinal Stro-mal Tumours: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 21, V98-V102. https://doi.org/10.1093/annonc/mdq208
|
[49]
|
Beham, A.W., Schaefer, I.M., Schüler, P., et al. (2012) Gastrointestinal Stromal Tumors. International Journal of Colorectal Disease, 27, 689-700. https://doi.org/10.1007/s00384-011-1353-y
|